Publications
Found 3 results
Filters: Author is S.-F. Lin [Clear All Filters]
,
“Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients”, vol. 12, pp. 5617-5622, 2013.
, “Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia”, vol. 11, pp. 317-321, 2012.
, Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, et al. (2002). Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 16: 1390-1393.
http://dx.doi.org/10.1038/sj.leu.2402634
PMid:12094265
Bumm T, Muller C, Al-Ali HK, Krohn K, et al. (2003). Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101: 1941-1949.
http://dx.doi.org/10.1182/blood-2002-07-2053
PMid:12411298
Deininger MW, Cortes J, Paquette R, Park B, et al. (2007). The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 110: 1509-1519.
http://dx.doi.org/10.1002/cncr.22936
PMid:17702093
Fabarius A, Giehl M, Frank O, Duesberg P, et al. (2005). Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 19: 1573-1578.
http://dx.doi.org/10.1038/sj.leu.2403861
PMid:15990860
Kharbanda S, Pandey P, Jin S, Inoue S, et al. (1997). Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 386: 732-735.
http://dx.doi.org/10.1038/386732a0
PMid:9109492
Kim M, Lee S, Jung CK, Lim J, et al. (2008). Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia. Int. J. Lab. Hematol. 30: 508-512.
PMid:18983302
Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, et al. (2006). Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108: 2811-2813.
http://dx.doi.org/10.1182/blood-2006-04-017400
PMid:16809614
Lin Y, Bruyere H, Horsman DE, Pantzar T, et al. (2006). Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet. Cytogenet. 170: 16-23.
http://dx.doi.org/10.1016/j.cancergencyto.2006.04.012
PMid:16965950
Loriaux M and Deininger M (2004). Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk. Lymphoma 45: 2197-2203.
http://dx.doi.org/10.1080/10428190410001723278
O’Brien SG, Guilhot F, Larson RA, Gathmann I, et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348: 994-1004.
http://dx.doi.org/10.1056/NEJMoa022457
PMid:12637609
Tanaka H, Tanaka K, Oguma N, Ito K, et al. (2004). Effect of interferon-alpha on chromosome abnormalities in treated chronic myelogenous leukemia patients. Cancer Genet. Cytogenet. 153: 133-143.
http://dx.doi.org/10.1016/j.cancergencyto.2004.01.019
PMid:15350303
Terre C, Eclache V, Rousselot P, Imbert M, et al. (2004). Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18: 1340-1346.
http://dx.doi.org/10.1038/sj.leu.2403399
PMid:15190256